Lmr Partners LLP Bio N Tech Se Transaction History

Lmr Partners LLP

$9.66 Billion
Q4 2024

A detailed history of Lmr Partners LLP transactions in Bio N Tech Se stock. As of the latest transaction made, Lmr Partners LLP holds 4,777 shares of BNTX stock, worth $572,427. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,777

Previous 51,000 90.63%

Holding current value

$572,427

Previous $6.06 Million 91.02%

% of portfolio

0.01%

Previous 0.06%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$99.72 - $122.68 $476,362 - $586,042	4,777 New	4,777 $544,000
Q2 2024 Aug 14, 2024	BUY	$80.36 - $102.87 $9.23 Million - $11.8 Million	114,846 New	114,846 $9.23 Million
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $11.8 Million - $14.9 Million	-119,372 Reduced 78.99%	31,748 $3.45 Million
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $2.12 Million - $2.68 Million	20,699 Added 15.87%	151,120 $16.3 Million
Q1 2023 May 15, 2023	BUY	$122.57 - $153.67 $10.6 Million - $13.3 Million	86,668 Added 198.08%	130,421 $16.2 Million
Q4 2022 Feb 14, 2023	SELL	$118.43 - $186.05 $6.03 Million - $9.48 Million	-50,941 Reduced 53.8%	43,753 $6.57 Million
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $1.55 Million - $2.22 Million	-12,123 Reduced 11.35%	94,694 $12.8 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $8.46 Million - $12.8 Million	68,606 Added 179.55%	106,817 $15.9 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $1.44 Million - $2.65 Million	-11,431 Reduced 23.03%	38,211 $6.52 Million
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $10.8 Million - $18 Million	49,642 New	49,642 $12.8 Million

Others Institutions Holding BNTX

# of Institutions

374

Shares Held

40.2M

Call Options Held

3.32M

Put Options Held

2.26M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.1B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.

Account